It seems some commentators in the broader market have also forgotten that the trial is at the stage of testing safety not efficacy. Whether it works or not is not even part of the parameter at this point, that comes next. So the fact that patients responded to previously redundant treatments is quite significant.
i dont get it., page-10
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(25.0%) |
Mkt cap ! $6.172M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $7.419K | 2.372M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 56 | 40557809 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 26688875 | 13 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| PAB (ASX) Chart |